Vista and Medtronic agree to part company:
This article was originally published in Clinica
Vista Medical Technologies and Medtronic have terminated the three agreements between them that related to selling Vista's Series 8000 visualisation and information system for cardiac procedures. Vista says the exclusive agreements were cancelled because the endoscopic bypass surgery market has failed to develop as the Carlsbad, California-based company had predicted. However, it says that it is negotiating with another "international cardiac products company" for worldwide exclusive distribution of the visualisation system.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.